Bispecific Therapies in RRMM: Teclistamab, Talquetamab, and Elranatamab Updates
Insight into the latest updates on three approved bispecific therapies in the context of relapsed and refractory multiple myeloma, including teclistamab, talquetamab, and elranatamab, discussing response rates, administration, and side effects.
EP: 1.Evolving Treatment Paradigms in Relapsed/Refractory Multiple Myeloma
EP: 2.Earlier Use of Novel Therapeutics in Multiple Myeloma Treatment Pathways
EP: 3.Patient Scenario: Management of Multiple Myeloma With Talquetamab Therapy
Now Viewing
EP: 4.Bispecific Therapies in RRMM: Teclistamab, Talquetamab, and Elranatamab Updates
EP: 5.Bispecific Therapies in Multiple Myeloma: Impact on Real-World Practice
EP: 6.Adverse Events With Bispecific Therapy: Dysgeusia, Skin, and Nail Changes
EP: 7.Managing AEs in Multiple Myeloma: Dosing and Prophylactic Strategies
EP: 8.Multiple Myeloma: Optimizing ICANS and CRS Management
EP: 9.Managing Toxicity Following Bispecific Therapy in R/R Multiple Myeloma
EP: 10.Patient Scenario: Navigating Sequencing in Multiple Myeloma
EP: 11.CAR-T vs BCMA Bispecifics: Navigating Myeloma Treatment Decisions
EP: 12.Navigating CAR-T Therapy in RRMM: Patient Counsel and Managing AEs
EP: 13.Advancements in Multiple Myeloma IO Therapy: Key Takeaways
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
